We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-19.25%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$585M
AUM Growth
-$382M
Cap. Flow
-$229M
Cap. Flow %
-39.19%
Top 10 Hldgs %
61.33%
Holding
429
New
88
Increased
84
Reduced
102
Closed
122

Top Buys

Rank Stock Value
1
ET icon
Energy Transfer Partners
ET
+$50.2M
2
EPD icon
Enterprise Products Partners
EPD
+$8.56M
3
OKE icon
Oneok
OKE
+$8.36M
4
AM
ANTERO MIDSTREAM PARTNERS LP
AM
+$3.06M
5
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$2.72M

Top Sells

Rank Stock Value
1
ETP
Energy Transfer Partners, L.P.
ETP
+$77.3M
2
MPC icon
Marathon Petroleum
MPC
+$28.8M
3
EEP
Enbridge Energy Partners
EEP
+$23.6M
4
PSX icon
Phillips 66
PSX
+$16.9M
5
WMB icon
Williams Companies
WMB
+$16.7M

Sector Composition

Rank Sector Weight
1 Energy 82.73%
2 Healthcare 7.29%
3 Utilities 2.06%
4 Financials 0.12%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGEN
126
Agenus
AGEN
$249M
$288K 0.05%
6,155
-2,405
-28% -$100K
KPTI icon
127
Karyopharm Therapeutics
KPTI
$168M
$288K 0.05%
2,048
+299
+17% +$50.4K
ABEO icon
128
Abeona Therapeutics
ABEO
$345M
$286K 0.05%
1,601
+410
+34% +$89.4K
KDMN
129
DELISTED
Kadmon Holdings, Inc.
KDMN
$286K 0.05%
+137,701
New +$347K
BCRX icon
130
BioCryst Pharmaceuticals
BCRX
$2.37B
$285K 0.05%
35,300
-48,170
-58% -$375K
CBIO
131
Crescent Biopharma
CBIO
$602M
$283K 0.05%
299
+11
+4% +$13.2K
RYTM icon
132
Rhythm Pharmaceuticals
RYTM
$7B
$283K 0.05%
10,512
-3,532
-25% -$97.6K
SAGE
133
DELISTED
Sage Therapeutics
SAGE
$282K 0.05%
2,948
+77
+3% +$8.81K
PRNB
134
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$282K 0.05%
+10,308
New +$266K
STML
135
DELISTED
Stemline Therapeutics, Inc.
STML
$282K 0.05%
29,723
+2,982
+11% +$38.7K
BOLD
136
DELISTED
Audentes Therapeutics, Inc
BOLD
$281K 0.05%
13,184
+1,053
+9% +$27.2K
TVRD
137
Tvardi Therapeutics
TVRD
$23.5M
$278K 0.05%
594
-190
-24% -$123K
RETA
138
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$278K 0.05%
4,956
-6,983
-58% -$426K
VYGR icon
139
Voyager Therapeutics
VYGR
$187M
$275K 0.05%
29,207
+7,338
+34% +$94.2K
RGNX icon
140
Regenxbio
RGNX
$623M
$274K 0.05%
6,522
-1,930
-23% -$113K
IMGN
141
DELISTED
Immunogen Inc
IMGN
$273K 0.05%
56,871
+11,759
+26% +$71.4K
MYOK
142
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$273K 0.05%
5,594
-4,072
-42% -$224K
CRNX icon
143
Crinetics Pharmaceuticals
CRNX
$8.86B
$271K 0.05%
+9,034
New +$254K
MGNX icon
144
MacroGenics
MGNX
$235M
$271K 0.05%
21,330
+301
+1% +$5.05K
CBAY
145
DELISTED
Cymabay Therapeutics
CBAY
$271K 0.05%
34,437
-1,683
-5% -$16K
EIDX
146
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$271K 0.05%
+19,676
New +$248K
PGNX
147
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$271K 0.05%
64,532
+12,534
+24% +$63.8K
INSM icon
148
Insmed
INSM
$23.2B
$270K 0.05%
20,606
+3,855
+23% +$61.5K
CRBP icon
149
Corbus Pharmaceuticals
CRBP
$170M
$269K 0.05%
1,538
-1,043
-40% -$208K
PRTA icon
150
Prothena Corp
PRTA
$458M
$267K 0.05%
25,882
-5,457
-17% -$64.9K
4 5
6
7 8

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q4 2018 Portfolio in Review

As of Q4 2018, Virtus ETF Advisers held 429 positions worth $585M, down 40% from $968M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Virtus ETF Advisers withdrew a net $229M in Q4 2018, closing 122 positions and reducing 102 holdings. Its most notable exit was Energy Transfer Partners, L.P., an estimated $77.3M position sold in full.

By sector, the portfolio is most concentrated in Energy at 83% of assets, up from 68% a quarter earlier, followed by Healthcare and Utilities.

Against the trend, Virtus ETF Advisers opened a new position in Amyris Inc. worth $251K.

  • Virtus ETF Advisers's largest Q4 2018 buy was Amyris Inc.: 75,294 shares worth $251K.
  • Virtus ETF Advisers added most to Energy Transfer Partners in Q4 2018, an estimated $50.2M increase.
  • Virtus ETF Advisers's biggest Q4 2018 reduction was Marathon Petroleum, cutting an estimated $28.8M.
  • Virtus ETF Advisers fully exited Energy Transfer Partners, L.P. in Q4 2018, selling an estimated $77.3M.
  • Virtus ETF Advisers's ten largest holdings make up 61% of its $585M portfolio in Q4 2018.
  • Virtus ETF Advisers opened 88 new positions and closed 122 in Q4 2018.
  • Virtus ETF Advisers's portfolio value fell 40% quarter-over-quarter to $585M.

Based on Virtus ETF Advisers's 13F filing for Q4 2018, filed 5 Feb 2019.